采用MonolixSuite软件发表的部分参考文献汇总（2024年7月-2025年12月）

采用MonolixSuite软件发表的部分参考文献汇总（2024年7月-2025年12月）

凡默谷技术部挑选了2024年7月—2025年12月全球采用MonolixSuite软件发表或涉及MonolixSuite综述的部分应用文章。希望对您的业务或专业学习有所帮助。

中国用户发表的部分文章或涉及到的综述

用于预测拓扑异构酶抑制剂ADC药物在小鼠及人体内的药代动力学、肿瘤生长抑制效应及毒性风险的 PBPK-PD 模型

PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans

Zehua Wang, Jinwei Zhu, Lan Sang, Linxiu Tang, Sasa Zhang, Yongmei Tan, Yanlin Zhao, Kun Hao. Eur J Pharm Sci. 2025 Oct 1:213:107234.

西维来司他钠在中国重症肺炎患者中的群体药代动力学研究

Population pharmacokinetics of sivelestat in Chinese patients with severe pneumonia

Zhang X., Hu H., Li Z., Zhang P., Pan L., Wang L., Mao J., Li F., Zhang L. Fundamental and Clinical Pharmacology. 2025 39:2 Article Number e70001

亚胺培南在感染性实体瘤患者中的群体药代动力学：一项真实世界研究

Population pharmacokinetics of imipenem in solid tumor patients with infections: A real-world study

Xu T., Zou T., Zhang J., Li Z., Li F., Du J., Hao Z. Journal of Global Antimicrobial Resistance. 2025 45 (107-114)

PopPK和PBPK模型指导美罗培南在重症患儿增强肾脏清除率下的剂量优化

PopPK and PBPK Models Guide Meropenem Dosing in Critically Ill Children with Augmented Renal Clearance

Liu Y., He H., Zhang S.-S., Zhou J., Zhu J.-W., Xu J., Miao H.-J., Chen J.-H., Hao K. Pharmaceutics. 2025 17:12 Article Number 1544

达泊西汀在健康中国男性受试者中的群体药代动力学

Population Pharmacokinetics of Dapoxetine in Healthy Chinese Male Subjects

Pu L., Wu T., Bai F., Lu H., Wang Y., Gao Y., Qiu W. Journal of Clinical Pharmacology. 2025

丙泊酚注射液的群体药代动力学研究进展

陈浩，陈建恒，吕洁，严泽林，卞民亮，陆程灿.

《临床药物治疗杂志》. 第24 卷 第1 期, 2026年1月

其他国家用户发表的部分文章或相关的综述

基于模型的荟萃分析应用 MonolixSuite：针对纵向分类与连续数据的教程

Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data
Bracis C., Taneja A., Lyauk Y.K., Barcomb H., de la Peña A., Cellière G.CPT: Pharmacometrics and Systems Pharmacology 2026 15:2 Article Number e70158 

高强度间歇性运动对二甲双胍在健康男性的药代动力学影响——基于PopPK模型的评估

Effect of high-intensity interval exercise on metformin pharmacokinetics in healthy men, assessed through a population pharmacokinetic model
Nikolaidis S., Kosmidis I., Papadopoulos S., Lioupi A., Gandanidou M., Gika H., Dokoumetzidis A., Theodoridis G., Mougios V. British Journal of Pharmacology. 2026 183:3 (438-452) 

抗胸腺细胞球蛋白在髓消性造血干细胞移植中的PopPK与最佳药物暴露

Population pharmacokinetics and optimal exposure of anti-thymocyte globulin in myeloablative hematopoietic cell transplantation
Ghazal H., Leuchter S., Ngo R., Kinzel M., Dabas R., DharmaniKhan P., Khan F.M., Jamani K., Li N., Kiang T.K., Storek J. Transplantation and cellular therapy. 2026 

他克莫司口服混悬液在造血干细胞移植患儿中的PopPK及生物利用度研究

Population pharmacokinetics and bioavailability of tacrolimus oral suspension in children with haematopoietic stem cell transplant
Brstilo L., Ibarra M., Juliá A., Testard J., Salgueiro R., Mendoza A., Pérez C., Licciardone N., Marquet P., Staciuk R., Buontempo F., Schaiquevich P. British Journal of Clinical Pharmacology.  2026 92:1 (210-219) 

从 AUC/MIC 到 AUCss 与 Cmin：通过模型引导米卡芬净在危重患者治疗中的精准给药的优化

From AUC/MIC to AUCss and Cmin: Optimizing Micafungin Therapy in the Critically Ill through Model-Informed Precision Dosing

Berrah R., Saint Marcoux F., Monchaud C., Cointault O., Conseil M., Jaber S., Jung B., Woillard J.B. AAPS Journal 2026 28:1 Article Number 18

阿莫西林在人乳中的PopPK建模——ConcePTION 项目的一项贡献

Population pharmacokinetic modelling of amoxicillin in human breast milk—A contribution from the ConcePTION project

Baklouti S., Rigourd V., Panchaud A., Nordeng H., Allegaert K., Annaert P., Huang M.-C., Monfort A., Guidi M., Gandia P. British Journal of Clinical Pharmacology. 2026

重症监护病房（ICU）收治的医院获得性肺炎患者中，他唑巴坦联合哌拉西林给药的关键阈值目标达标率

Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia

Williamson R., Zurawska M., Valadez A., Harlan E., Scheetz M.H., et al. Antimicrobial agents and chemotherapy. 2025 (e0176625-)

含删失协变量和测量误差的广义线性混合模型及其在 HIV/AIDS 研究中的应用

Generalized Linear Mixed Models with Censored Covariates and Measurement Errors, with Applications in HIV/AIDS Studies

Gao S., Wu L. Statistics in Biosciences. 2025 17:3 (832-854)

神经重症监护人群中左乙拉西坦给药方案的优化：Neuro-ARC 研究

Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC Study

Kharouba M., Cook A.M., Bastin M.L.T., Kutsogiannis D.J., Mahmoud S.H. Neurocritical Care. 2025 43:3 (887-901)

结合人胎盘离体灌注数据与PBPK建模预测艾司西酞普兰、舍曲林和帕罗西汀在母亲及胎儿中的药物暴露

Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling

Préta L.-H., Bouazza N., Foissac F., Froelicher L., Urien S., Buth V., Benaboud S., Tréluyer J.-M., Lui G. Clinical Pharmacokinetics. 2025 64:12 (1843-1854)

ADC药物的上市后评估：基于模型荟萃分析和临床效用指数方法支持临床概念验证

Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach

Asiimwe I.G., Chtiba N., Mouksassi S., Pillai G., Peter R.M., Yuen E., Pilla Reddy V. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:11 (1810-1822)

基于全身动态 PET 微剂量给药数据建立人体格列吡嗪全身药代动力学预测模型

Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in Humans

Comin L., Marie S., Ursino M., Zohar S., Tournier N., Comets E. Clinical Pharmacokinetics. 2025 64:11 (1709-1722)

家庭接触者中 SARS-CoV-2 检测的时间动态：首次阳性检测时间、症状出现时间与病毒载量峰值时间的差异

Temporal Dynamics of SARS-CoV-2 Detection in Household Contacts: Divergences Between Time to First Positive Test, Symptom Onset, and Maximum Viral Load

Berger A., Groh A.M., Diaz D., Canchola J.A., Toptan T., Ciesek S., Jarem D., Kuchta A.L., Moonsamy P., Vehreschild M.J.G.T. Infectious Diseases and Therapy. 2025 14:11 (2605-2617)

成人肺移植受者术后早期霉酚酸PopPK及贝叶斯评估

Population pharmacokinetics of mycophenolic acid and Bayesian estimator in lung transplant adults recipients in the early post-transplant period

Kauv J., Feuillet S., Barrail-Tran A., Delemos A., Legrand T., Verstuyft C., Le Pavec J., Comets E., Furlan V. European Journal of Pharmaceutical Sciences. 2025 214 Article Number 107290

抗中性粒细胞胞浆抗体（ANCA）相关性血管炎中利妥昔单抗诱导与维持治疗方案的比较：基于真实世界患者 ANCA 及丙种球蛋白水平的PK/PD分析

Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients

Pasquiers B., Blanchet B., Puéchal X., Declèves X., Cohen P., Goulvestre C., Casadevall M., Benhabiles I., Vidal M., Ternant D., Terrier B., Puszkiel A. eBioMedicine. 2025 121 Article Number 105989

pH 值对德拉沙星抗大肠杆菌等基因株抗菌活性的影响：针对不同染色体和质粒介导的氟喹诺酮类耐药机制的研究

Effect of pH on antimicrobial activity of delafloxacin against Escherichia coli isogenic strains carrying diverse chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms

Alexandre K., Murillo-Torres M., Docobo-Pérez F., Pascual Á., Rodríguez-Martínez J.M. Microbiology spectrum. 2025 (e0233825-)

头孢唑林在儿科心脏手术患者中作为预防用药的PopPK研究

Population pharmacokinetics of cefazolin administered as prophylaxis in paediatric patients undergoing cardiac surgery

Cheng V., Suna J., Liu X., Moloney G., Marathe S.P., Parker S., Ungerer J.P.J., McWhinney B., Venugopal P., Alphonso N., Roberts J.A. Anaesthesia, critical care & pain medicine. 2025 (101653-)

比较 COVID-19 疫苗接种后未感染者和康复者随时间变化的中和抗体活性

Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individuals

Pillis L., Caffrey R., Chen G., Dela M., Eldevik L., Liu H., McConnell J.P., Shabahang S., Varvel S.A. Scientific reports. 2025 15:1 (34800-)

泼尼松龙在系统性红斑狼疮患者中的PopPK建模：暴露量与疾病活动度分析

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity

Bouazza N., Semeraro M., Lui G., et al. British Journal of Clinical Pharmacology. 2025 91:10 (2854-2864)

利妥昔单抗治疗多发性硬化症临床预试验中的PK-PD建模：迈向个性化给药间隔的研究

Pharmacokinetic–pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval

Serkland T.T., Skrede S., Hallin E.I., Myhr K.-M., Torkildsen Ø., Röblitz S. British Journal of Clinical Pharmacology. 2025 91:10 (2988-2997)

采用PopPK模型优化危重症难治性和超难治性癫痫持续状态患者的苯巴比妥给药方案

Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model

Stoschus M., Schmidbauer M.L., Starp J., Kunst S., Gakis G., Paal M., Vogeser M., Scharf-Janssen C., Liebchen U., Dimitriadis K. Epilepsia. 2025 66:10 (3757-3768)

妊娠对囊性纤维化女性患者中 elexacaftor、tezacaftor 和 ivacaftor 药代动力学的影响

Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in cystic fibrosis women

Magnas P., Bouazza N., Foissac F., Froelicher-Bournaud L., Lui G., Carlier N., Da Silva J., Fesenbeckh J., Kanaan R., Honoré I., Martin C., Treluyer J., Tsatsaris V., Burgel P., Benaboud S. Journal of Cystic Fibrosis. 2025 24 Supplement 2 (S279a-S280)

HIV 感染者中比克替拉韦的群体药代动力学：真实世界研究

Population pharmacokinetics of bictegravir in real-world people with HIV

Ekobena P., Briki M., Dao K., Marzolini C., et al. Journal of Antimicrobial Chemotherapy. 2025 80:10 (2782-2789)

社区获得性肺炎重症患者经持续输注高剂量头孢吡普后的肺内浓度研究

Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia

Roger C., Allaouchiche B., Quintão De Moraes D., Ulrich Feudjio O., Occean B.-V., Friggeri A., Lefrant J.-Y., Muller L., Breilh D. Journal of Antimicrobial Chemotherapy. 2025 80:10 (2644-2653)

血管紧张素 II/血管紧张素 I 比值作为接受依那普利治疗的健康成年受试者和心力衰竭儿童患者群体建模的一项新的药效学参数

Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril

Steichert M., Cawello W., Burckhardt B.B., Suessenbach F.K., Laeer S. Pharmaceutics. 2025 17:10 Article Number 1345

精确调整达托霉素给药剂量：3 种、2 种、1 种及 0 浓度取样方案比较

Precision Daptomycin Dosing: Comparison of 3-, 2-, 1-, and 0-Concentration Sample Strategies

Giuliano S., Pai M.P., Angelini J., Flammini S., Martini L., Baraldo M., Tascini C. Pharmacotherapy. 2025 45:9 (540-546)

针对接受肾脏替代治疗的危重患者的美罗培南和哌拉西林/他唑巴坦优化给药方案

Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy

Roberts J.A., Ulldemolins M., Liu X., et al. Intensive Care Medicine. 2025 51:9 (1628-1640)

基于PopPK模型优化利奈唑胺给药方案：针对疑似或确诊革兰阳性菌败血症的血液肿瘤患者

Population Pharmacokinetic Model-Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram-Positive Sepsis

Zavřelová A., Merdita S., Žák P., Radocha J., Víšek B., Lánská M., Maláková J., Michálek P., Slanař O., Šíma M. Clinical and Translational Science. 2025 18:9 Article Number e70346

IgG 编码 mRNA的多尺度机理药代动力学—毒代动力学（PK-TK）建模在基础研究到临床的应用：以抗 Claudin 18.2 抗体为例

Bench to Bedside Modeling of mRNA Encoding IgG Using a Multiscale Mechanistic Pharmacokinetic-Toxicokinetic (PK-TK) Model: A Case Study With Anti-Claudin 18.2

Desai D.A., Cristofoletti R. Clinical and Translational Science. 2025 18:9 Article Number e70356

使用 SVG-101 群体药动学模型评估其合理的剂量选择

Application of population pharmacokinetic modeling of SVG-101 to evaluate proper dose selection

Mo K.H., Chae D., Jung Y.S., Jin B.H., Keum D.H., Choi M.K., Cha J.S., Park M.S., Kim C.O. Translational and Clinical Pharmacology. 2025 33:3 (156-167)

2 型糖尿病患者代谢年龄和实际年龄vs碘海醇药代动力学的相关性

Correlation of Metabolic Age & Calendar Age to Iohexol Pharmacokinetics in Patients With Type 2 Diabetes

Alikhani R., Hooper L., Matvekas A., Waltje A., Rothberg A., Pai M. Clinical Pharmacology in Drug Development. 2025 14 Supplement 1 (6-7)

通过群体PK/PD模拟评估替格瑞洛给药剂量中断及恢复治疗（含或不含负荷剂量）的效果

Evaluation of the Effect of Ticagrelor Dose Interruption and Treatment Resumption with or without Bolus Doses Through Population PK/PD Simulation

Matsui H., Pham L.T.T., Adane E. European Journal of Drug Metabolism and Pharmacokinetics. 2025 50:5 (409-418)

缬更昔洛韦预防巨细胞病毒感染的目标达成情况

Target attainment of valganciclovir prophylaxis against cytomegalovirus

Wenker S., Van Hasselt C., Moes D., Märtson A. British Journal of Clinical Pharmacology. 2025 91 Supplement 1 (8-9)

胺碘酮对心脏手术后患者中阿哌沙班药物暴露的影响：一项群体药代动力学研究

Effect of Amiodarone on Apixaban Exposure in Patients after Cardiac Surgery—A Population Pharmacokinetic Study

Morath B., Foerster K.I., Chiriac U., Zaradzki M., Hoppe-Tichy T., Schrey D., Burhenne J., Czock D., Karck M., Haefeli W.E., Wicha S.G. Clinical Pharmacokinetics. 2025 64:8 (1191-1201)

非甾体抗炎药在山地超级越野跑者干血斑中的定量分析：PK模型对结果解读的贡献

Quantitative analysis of nonsteroidal anti-inflammatory drugs in dried blood spot from mountain ultra-trail runners. Contribution of pharmacokinetic models for the interpretation of the results

Mashal M.S., Guitton J., Sallet P., Bourguignon L., Machon C. Drug Testing and Analysis. 2025 17:6 (825-833)

比较不同胰岛素类型的疗效：健康受试者葡萄糖钳夹效应的PK-PD建模

Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers

Chang Y.C., Jusko W.J. Journal of Clinical Pharmacology. 2025 65:8 (999-1010)

评估多重插补算法对PK模型性能的影响：一项基于模拟的研究

Assessing the Impact of Multiple Imputation Algorithms on Pharmacokinetic Model Performance: A Simulation-Based Study

Duflot T., Fayette L., Konecki C., Seurat J., Feliu C., Scala-Bertola J., Djerada Z. AAPS Journal. 2025 27:4 Article Number 77

量化影响常染色体显性肾小管间质肾病进展速度和严重程度的临床及遗传因素

Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progression

Ramesh S.S., Rogge M., Kidd K.O., Williams A.H., Yoon D.Y., Roignot J., Blakeslee K., Bleyer A.J., Kim S. Journal of Pharmacokinetics and Pharmacodynamics. 2025 52:4 Article Number 41

甲氨蝶呤的治疗药物监测、PopPK建模及在儿童急性淋巴细胞白血病患者高剂量给药的外部验证

Therapeutic Drug Monitoring, Population Pharmacokinetics Models, and External Validation of High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia

Maximova N., Calabrò P.F., Cangialosi A., Di Paolo A. Chemotherapy. 2025 70:3 (109-118)

危重症儿童尿液生物标志物与头孢吡肟治疗目标达成的关联研究

Urinary Biomarkers and Attainment of Cefepime Therapeutic Targets in Critically Ill Children

Downes K.J., Sharova A., Amajor V., Gianchetti L., Himebauch A.S., Fitzgerald J.C., Zuppa A.F. Pediatric Infectious Disease Journal. 2025 44:8 (749-754)

Andalusian马体内静脉注射对乙酰氨基酚及其代谢物后的群体药代动力学和临床评估研究

Population pharmacokinetics and clinical evaluation of intravenous acetaminophen and its metabolites in Andalusian horses

Granados M.M., Medina-Bautista F., Navarrete-Calvo R., Argüelles D., Domínguez-Pérez J.M., Priego-Capote F., Muñoz-Rascón P., Serrano-Rodríguez J.M. Veterinary Journal. 2025 312 Article Number 106357

预测妊娠期间他克莫司的游离浓度

Predicting Unbound Tacrolimus Concentrations during Pregnancy

Leino A., Wilson N.K., Kataria A.D., Hebert M.F. American Journal of Transplantation. 2025 25:8 Supplement 1 (S204-)

AEROfen：一项 I 期临床、开放标签、随机交叉研究方案，通过PK模型评估健康受试者中雾化芬太尼的给药效率—比较面部与鼻内给药途径

AEROfen: protocol for a phase I, open-label, randomised crossover study evaluating the efficiency of nebulised fentanyl in healthy volunteers - comparing facial versus intranasal administration via pharmacometric modelling

Follet C., Dumont A., Roussel M., Gillibert A., Boedard C., Quillard M., Ruault S., Vallin F., Donnadieu N., Nunes Ferreira D., Pereira T., Joly L.-M., Lvovschi V., Duflot T. BMJ Open. 2025 15:7 Article Number e091125

超越线性模型的浓度- QT 分析

Beyond the linear model in concentration‑QT analysis

Géraldine Cellière, Andreas Krause, Guillaume Bonnefois, Jonathan Chauvin. Journal of Pharmacokinetics and Pharmacodynamics. (2025) 52:31

1 型干扰素介导的系统性红斑狼疮炎症的综合机制模型

An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus Erythematosus

Volkova A., Sokolov V., Tettamanti F., Verma M., Ugolkov Y., Peskov K., Tang W., Kimko H. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:7 (1225-1235)

PK/PD建模与蒙特卡洛模拟预测接受（缬）更昔洛韦治疗的儿科移植受者的巨细胞病毒载量

Pharmacokinetic/Pharmacodynamic Modelling and Monte Carlo Simulations to Predict Cytomegalovirus Viral Load in Pediatric Transplant Recipients Treated with (val) Ganciclovir

Koloskoff K., Franck B., Benito S., Welzel J., Autmizguine J., Theoret Y., Briand A., Ovetchkine P., Woillard J.-B. Clinical Pharmacokinetics. 2025 64:7 (1061-1069)

沙特阿拉伯儿童肝移植术后早期他克莫司药代动力学的一项回顾性分析

A retrospective analysis of tacrolimus pharmacokinetic in Saudi paediatric patients in early post-liver transplantation period

Alghanem A., Joharji H., Garaween N., Alenazi H., Alsaleh N.A., Broering D., Alshagrani M., Alhassan F., Albassam A.A., Alsultan A., Alsmari A. Pediatrics and Neonatology. 2025 66:4 (368-374)

利用纵向患者报告结局轨迹预测非小细胞肺癌生存期

Leveraging Longitudinal Patient-Reported Outcome Trajectories to Predict Survival in Non–Small Cell Lung Cancer

Zhou J., Muluneh B., Wang Z., Yao H., Hughes J.H. Clinical Cancer Research. 2025 31:13 (2685-2694)

理解与优化剂量探索：从剂量模拟到剂量估算

Understanding and Streamlining Dose Finding: From Dose Simulation to Dose Estimation

Bräm D., Bachmann F., Schropp J., Gotta V., Steffens B., van den Anker J., Pfister M., Koch G. Journal of Clinical Pharmacology. 2025 65:6 (731-741)

基于模型的方法评估抗药物抗体对生物制剂药物暴露的影响：以 CD3 T 细胞双特异性抗体赛必妥单抗为例

A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific Cibisatamab

Sanchez J., Pierrillas P.B., Frey N., Lotz G.P., Jönsson S., Friberg L.E., Frances N. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:6 (1065-1076)

基于治疗药物监测, 考察阿米卡星在教学医院患者中的群体药代动力学

Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching Hospital

Steffens N.A., Zimmermann E.S., Azeredo F.J., Linden R., Finatto L.J., Hahn R.Z., Schwarzbold A.V., Pacheco L.S., Brucker N. Antibiotics. 2025 14:6 Article Number 531

辅助靶点的药效学评估：低分子量 PBP7/8 对β-内酰胺类药物抗碳青霉烯耐药鲍曼不动杆菌活性的影响

Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter Baumannii

Ho B.M., Jin J., Sanborn J.T., Nguyen T.D., Singh N., Cheng C., Nasief N.N., Carlino-MacDonald U., Tsuji B.T., Zhao Y., Chen L., Moya B., Russo T.A., Smith N.M. Pharmaceuticals. 2025 18:6 Article Number 918

WS02.06 Elexacaftor/tezacaftor/ivacaftor在 2 至 5 岁儿童中的药代动力学及行为障碍发生情况

WS02.06Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurrence of behavioural disorders in children aged 2 to 5 years old

Truong N.H., Benaboud S., Chouchana L., Bonnel A.-S., Barboura M., Bouazza N., Gautier S., Rouillon S., Froelicher-Bournaud L., Bihouee T., Bui S., Treluyer J.-M., Gaudelus I.S., Foissac F., Modul-CF research group. Journal of Cystic Fibrosis. 2025 24 Supplement 1 (S5-)

老年群体中皮下注射与静脉注射头孢曲松的药代动力学：PhASAge 研究

Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone in an Older Population: The PhASAge Study

Roubaud-Baudron C., Fauchon H., Stanke-Labesque F.,et al. Open Forum Infectious Diseases. 2025 12:6 Article Number ofaf313

感染后期植入的 SIV 前病毒存在于寿命较短的 CD4+ T 细胞中

SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells

Sambaturu N., Fray E.J., Hariharan V., Wu F., Zitzmann C., Simonetti F.R., Barouch D.H., Siliciano J.D., Siliciano R.F., Ribeiro R.M., Perelson A.S., Molina-París C., Leitner T. Cell Reports. 2025 44:5 Article Number 115663

一箭多雕：用于多适应症的肠溶型霉酚酸钠的PopPK模型及贝叶斯估算

Killing several birds with one stone: A multi-indication population pharmacokinetic model and Bayesian estimator for enteric-coated mycophenolate sodium

Fromage Y., Sayadi H., Koloskoff K., Marquet P., Labriffe M., Monchaud C., Woillard J.-B. British Journal of Clinical Pharmacology. 2025 91:5 (1396-1408)

通过PopPL分析优化 1-3 级肥胖患者静脉注射利多卡因的给药方案

Dosing optimisation of intravenous lidocaine in patients with class 1–3 obesity by population pharmacokinetic analysis

Tognolini A.R., Liu X., Pandey S., Roberts J.A., Wallis S.C., Jackson D., Eley V.A. Anaesthesia. 2025 80:5 (511-521)

用于考察阿替洛尔与美托洛尔在营养不良大鼠体内吸收的迷你PBPK模型

Minimal Physiologically-Based Pharmacokinetic Modeling of Atenolol and Metoprolol Absorption in Malnourished Rats

Kir F., Sahin S., Jusko W.J. European Journal of Drug Metabolism and Pharmacokinetics. 2025 50:3 (251-263) Article Number e115

Elexacaftor/Tezacaftor/Ivacaftor在囊性纤维化儿科患者中的群体药代动力学研究

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis

Truong N.H., Benaboud S., Bouazza N., Barboura M.,et al. Clinical and Translational Science. 2025 18:5 Article Number e70245

比较妊娠妇女在惊厥前期使用 75 mg与 150 mg阿司匹林的效果

Comparing 75mg vs 150mg aspirin in pregnancy women at risk of preeclampsia

Vinogradov R., Kavanagh O.N., Kamali F., Robson S. American Journal of Obstetrics and Gynecology. 2025 232:5 (e189-e190)

克林霉素与利福平联合用药的剂量及给药途径

Dosing and route of administration of clindamycin given in combination with rifampicin

Magréault S., Berrah R., Kerroumi Y., Mimram L., Salmon D., Goulenok T., de la Selle A., Lefort A., Marmor S., Helali N.H., Zeller V., Jullien V. Clinical Microbiology and Infection. 2025 31:5 (832-838)

舒更葡糖或新斯的明逆转维库溴铵诱导犬神经肌肉阻滞的速度：随机临床试验与药理学建模

Speed of reversal by sugammadex or neostigmine after vecuronium-induced neuromuscular block in dogs: Randomized clinical trial and pharmacological modeling

Martin-Flores M., Lorenzutti A.M., Markmann A.D., Araos J., Campoy L. Veterinary Anaesthesia and Analgesia. 2025 52:3 (328-337)

阿昔洛韦及其主要代谢产物 9-羧甲氧基甲基鸟嘌呤在早期肝移植受者中的群体药代动力学及伐昔洛韦的安全性评估

Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipients

Kably B., Briard M., Francoz C., Roux O., Houhou N., Mackiewicz V., Peytavin G., Durand F., Lê M.P. Journal of Antimicrobial Chemotherapy. 2025 80:5 (1302-1308)

一种用于治疗慢性乙型肝炎的衣壳蛋白装配调节剂作用的多尺度模型

A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B

Iyaniwura S.A., Cassidy T., Ribeiro R.M., Perelson A.S. PLoS Computational Biology. 2025 21:5 Article Number e1012322

左乙拉西坦药代动力学在真实世界中的患者间变异性

Real-world interpatient variability in the pharmacokinetics of levetiracetam

Chykharivska A., Kagan L., Wagner M., Brunetti L. Fundamental and Clinical Pharmacology. 2025 39:2 Article Number e13059

接受连续性肾脏替代治疗的危重患者是否需要调整头孢洛林给药剂量？基于回顾性数据的头孢洛林PopPK模型及目标达成概率分析的剂量模拟

Do Critically Ill Patients Undergoing Continuous Renal Replacement Therapy Require Ceftaroline Dosage Adjustments? Ceftaroline PopPK Model and Dosage Simulations with the Probability of Target Attainment Analysis Based on Retrospective Data

Adamiszak A., Pietrzkiewicz K., Bartkowska-Śniatkowska A., Smuszkiewicz P., Kusza K., Grześkowiak E., Bienert A. Antibiotics. 2025 14:4 Article Number 347

胶质母细胞瘤患者中帕米帕利总药量及游离药量的PopPK建模：药物处置机制解析与给药方案优化

Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization

Wickramasinghe C., Kim S., Jiang Y., Bao X., Yue Y., Jiang J., Hong A., Sanai N., Li J. Pharmaceutics. 2025 17:4 Article Number 524

美罗培南在严重细菌感染患者中的群体药动学与基于模型的给药方案优化

Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection

Murínová I., Švidrnoch M., Gucký T., Rezáč D., Hlaváč J., Slanar O., Šíma M. European Journal of Hospital Pharmacy. 2024 31:3 (253-258)

万古霉素在越南儿科患者治疗药物监测中的PopPK建模及中点浓度便捷采样

Population Pharmacokinetic Modeling and Convenient Sampling of Midpoint Concentration for Therapeutic Drug Monitoring of Vancomycin in Vietnamese Pediatric Patients

Hai L.B., Kien P.C., Dua N.T., Hao N.T., Hung V.M., Hai N.T., Le J., Huong N.T.L. Pharmaceutical Sciences Asia. 2024 51:3 (241-249)

影响万古霉素谷浓度的因素：沙特非重症监护患者的PopPK模型

Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi Patients

Alqurain A.A., Alrashidi L.N., Aloraifej S.K., et al. Drug Design, Development and Therapy. 2024 18 (6185-6198)

Orvacabtagene Autoleucel, 一种自体 BCMA 导向的CAR-T 细胞产品在治疗复发/难治性多发性骨髓瘤患者中的PopPK研究

Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma

Hu H., Li Y., Piasecki J., Hosseyni D., Yan Z., Liu X., Ogasawara K., Zhou S., Cheng Y. Clinical Cancer Research. 2025 31:6 (1163-1171)

建模分析表明，奈玛特韦-利托那韦治疗后出现的 SARS-CoV-2 病毒反弹，是由靶细胞得以保留与病毒清除不彻底共同导致的

Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance

Phan T., Ribeiro R.M., Edelstein G.E., Boucau J., et al. Journal of Virology. 2025 99:3

用于癌症药物PK-PD建模与模拟的多器官芯片

Multiorgan-on-a-chip for cancer drug pharmacokinetics-pharmacodynamics (PK-PD) modeling and simulations

Mohammed A.E., Kurucaovalı F., Okvur D.P. Journal of Pharmacokinetics and Pharmacodynamics. 2025 52:1 Article Number 1

NX210c多肽在健康老年受试者中的安全性、耐受性及PK-PD关系研究：一项随机、安慰剂对照、双盲、多剂量递增试验

Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study

Janus A., Dumas D., Le Douce J., Marie S., Pasculli G., Bambury P., Lemarchant S., Kremer P., Godfrin Y. Neurology and Therapy. 2025 14:1 (357-377) Article Number 683783

卡泊芬净在接受体外膜氧合治疗的危重患者中的PopPK研究——ASAP ECMO 研究

Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study

Abdul-Aziz M.H., Diehl A., Liu X., Cheng V., Corley A., Gilder E., Levkovich B., McGuinness S., Ordonez J., Parke R., Pellegrino V., Wallis S.C., Fraser J.F., Shekar K., Roberts J.A. Antimicrobial Agents and Chemotherapy. 2025 69:2

肾功能不全患者中哌拉西林剂量调整：无论是否接受肾脏替代治疗, 均需增加达到目标暴露量

Dosing of Piperacillin in Altered Renal Function with and without Renal Replacement Therapy for Required Increased Exposition

Surat G., Dohmann E., Scherf-Clavel O., Kurlbaum M., Hagel S. Open Forum Infectious Diseases 2025 12 Supplement 1 (S798-)

重症成人鲍曼不动杆菌感染患者口服米诺环素的PK模型

Phamacokinetic Model of Oral Minocycline in Critically Ill Adult Patients with Acinetobacter baumannii Infection

Koumaki V., Athanassa Z., Valsami G., Papakyriakopoulou P., Saitani E.-M., Marques S., Manioudaki S., Sakagianni A., Dokoumatzidis A., Tsakris A. Open Forum Infectious Diseases. 2025 12 Supplement 1 (S801-)

使用容积吸收微量采样法研究多器官功能障碍综合征危重患儿中的万古霉素群体药代动力学

Vancomycin Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children with Multiple Organ Dysfunction Syndrome

Shiau J., Amajor V., Rhodes N.J., Zuppa A., Downes K.J., Takyi-Williams J., Wen B., Scheetz M.H. Open Forum Infectious Diseases. 2025 12 Supplement 1 (S788-S789)

粒细胞集落刺激因子的群体PK-PD建模以优化 CD34+细胞采集的给药剂量与给药时机

Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony-Stimulating Factor to Optimize Dosing and Timing for CD34+ Cell Harvesting

Xu Jiang, Jun Seok Cha, Byung Hak Jin, Choon Ok Kim, Dongwoo Chae. Clinical and Translational Science, 2025; 18:e70121

基于PopPK模型，为接受血液透析的肥胖患者群体制定万古霉素负荷剂量个体化给药方案

Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model

Polášková L., Hartinger J.M., Murínová I., Michálek P., Slanař O., Šíma M. Journal of Chemotherapy. 2025 37:2 (121-129)

考虑个体间变异的低维神经常微分方程在 Monolix 和 NONMEM 中的实现

Low-dimensional neural ordinary differential equations accounting for inter-individual variability implemented in Monolix and NONMEM

Bräm D.S., Steiert B., Pfister M., Steffens B., Koch G. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:1 (5-16)

瑞德西韦及其代谢物在健康受试者和肾功能不全患者中的药代动力学模拟

Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment

Zhang S., Jeong S., Jiang B., Ho H. Frontiers in Pharmacology. 2025 16 Article Number 1488961

群体PK/PD分析证实 SB16 与参比药物地舒单抗具有生物相似性

Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab

Choi S., Park S., Jung J., Baek S., Lim H.-S. Frontiers in Pharmacology. 2025 16 Article Number 1631034

肠溶阿司匹林胶囊与片剂在健康受试者群体中的PK-PD研究

Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy Subjects

Koh J., Khwarg J., Yu K.-S., Lee S., Jang I.-J., Lee S. Drug Design, Development and Therapy. 2025 19 (7853-7863)

结核病治疗中剂量精准的重要性

The importance of getting the dose right in the treatment of tuberculosis

Dudnyk A., Lutchmun W., Duarte R., Lange C., Svensson E.M. Breathe. 2025 21:1 Article Number 240177

瑞舒伐他汀和依折麦布联合用药导致肠肝循环的群体PK-PD研究

Population Pharmacokinetics and Pharmacodynamics with Enterohepatic Recirculation of Co-Medication of Rosuvastatin and Ezetimibe

An H., Shin D. Drug Design, Development and Therapy. 2025 19 (4777-4787)

在美国未感染 HIV 的成人中单独使用抗HIV-1 单克隆抗体 PGT121.414.LS，及与VRC07-523LS 联合给药的安全性、耐受性、药代动力学及中和活性研究（项目编号HVTN 136/HPTN 092）：一项首次人体、开放标签、随机对照的 1 期临床试验

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S., Hurt C.B., Stephenson K.E., Huang Y., et al. The Lancet HIV. 2025 12:1 (e13-e25)

恩诺沙星在治疗肉鸡大肠杆菌病中的PK、PD预测指标及蒙特卡洛模拟研究

Pharmacokinetics, pharmacodynamic efficacy prediction indices, and Monte Carlo simulations of enrofloxacin for the treatment of colibacillosis in broiler chickens

Felix L.A., Egito B.M., David D.D., Zangeronimo M.G., Wosiacki S.R., Ferrante M. Open Veterinary Journal. 2025 15:9 (4454-4469)

卡铂在犬类中的PopPK建模及其临床剂量调整

Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogs

Béguin J., Mahfoudhi S., Uzel M., Rostang A., Ibish C., Ferran A.A., Pelligand L., Hulin A., Kohlhauer M. BMC Veterinary Research. 2024 20:1 Article Number 575

Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring Concentrations

Al-Zubaydi F., Wassef A., Kagan L., Brunetti L. Pharmaceutics. 2024 16:12 Article Number 1514

阿莫西林对犬类假中间葡萄球菌PK-PD评价

Pharmacokinetics and Pharmacodynamics Evaluation of Amoxicillin Against Staphylococcus pseudintermedius in Dogs

Jeong J.-S., Kim J.-W., Kim J.-H., Kim C.-Y., Chung E.-H., Boo S.-Y., Lee S.-H., Ko J.-W., Kim T.-W. Pathogens. 2024 13:12 Article Number 1121

膳食和制剂对耐药性发育性及癫痫性脑病患儿体内大麻二酚全身暴露的影响

Impact of food and formulation on cannabidiol systemic exposure in children with drug-resistant developmental and epileptic encephalopathies

Brstilo L., Reyes G., Ibarra M., Cáceres Guido P., Bressan I., Marin M.N., Delaven S.F., Agostini S., Pérez Montilla C., López M.E., Cresta A., García Bournissen F., Schaiquevich P., Caraballo R. Epilepsia. 2024 65 Supplement 1 (492-)

基于模型荟萃分析建立复方口服避孕药突破性出血模型

Development of breakthrough bleeding model of combined-oral contraceptives utilizing model-based meta-analysis

Chen H., Chun D., Lingineni K., Guzy S., Cristofoletti R., Hoechel J., Jiao T., Cicali B., Vozmediano V., Schmidt S. CPT: Pharmacometrics and Systems Pharmacology. 2024 13:11 (2016-2025)

静脉注射免疫球蛋白在治疗各类免疫系统疾病患者中的PopPK模型

Population Pharmacokinetic Model of Intravenous Immunoglobulin in Patients Treated for Various Immune System Disorders

Lee J.L., Mohamed Shah N., Makmor-Bakry M., Islahudin F., Alias H., Mohd Saffian S. Clinical Therapeutics. 2024 46:12 (e25-e37)

持续输注哌拉西林/他唑巴坦可优化择期盆腔摘除术患者术中抗生素暴露水平

Continuous infusion of piperacillin/tazobactam optimizes intraoperative antibiotic exposure in patients undergoing elective pelvic exenteration surgery

Jackson D., Ulldemolins M., Liu X., Harris C., Tognolini A., Wallis S.C., Sumi C., Parker S.L., Eley V., Roberts J.A. Antimicrobial Agents and Chemotherapy. 2024 68:12

接受单倍体相合干细胞移植并采用移植后环磷酰胺/环孢素 A 为基础的移植物抗宿主病预防方案的患者中，霉酚酸暴露量降低—需加强剂量调整

Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis - Need for Dose Intensification

Pai A.A., Panetta J.C., Bijukumar N., Renji R.M., A M., Jayaraman A., Karumathil S., Korula A., Selvarajan S., Srivastava A., Abraham A., Mathews V., George B., Kulkarni U., Balasubramanian P. Blood. 2024 144 Supplement 1 (2150-)

不同剂量的甲氨蝶呤在类风湿关节炎患者中的PK-PD建模与模拟

Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis

Tan J.M., Upton R.N., Foster D.J.R., Proudman S.M., Dhir V., Wiese M.D. British Journal of Clinical Pharmacology. 2024 90:11 (2763-2780)

研究丙泊酚作为单一药物对 2-12 岁儿童双频谱指数峰值效应时间的影响

Understanding time to peak effect of propofol as sole agent on bispectral index in children aged 2–12 years

Gavel G., Koch G., Terrier A., Atkinson A., Pfister M., Erb T. Paediatric Anaesthesia. 2024 34:10 (1019-1028)

替扎帕林（一种皮下注射普通肝素的替代药物）用于重度及终末期肾功能不全患者的回顾性单中心观察性研究

Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study

Gouin-Thibault I., Mansour A., Caribotti C., et al.. Journal of Thrombosis and Haemostasis. 2024 22:10 (2864-2872)

麦考酚酸酯在印度狼疮性肾炎患者群体中的PopPK及有限采样策略研究

Population Pharmacokinetics and Limited Sampling Strategy of Mycophenolate Mofetil for Indian Patients With Lupus Nephritis

Koloskoff K., Panwar R., Rathi M., Mathew S., Sharma A., Marquet P., Benito S., Woillard J.-B., Pattanaik S. Therapeutic Drug Monitoring. 2024 46:5 (567-574)

通过建模与模拟确定儿科重症监护室中美罗培南的最佳给药策略

Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation

Junior R.M., Mizuno T., Paice K.M., Pavia K.E., Rhodes Hambrick H., Tang P., Jones R., Gibson A., Stoneman E., Curry C., Kaplan J., Girdwood S.T. Journal of Antimicrobial Chemotherapy. 2024 79:10 (2668-2677)

给药剂量是否得当？重症儿童患者中头孢吡肟的PopPK研究

Are We Dosing Correctly? Population Pharmacokinetics of Cefepime in Critically Ill Pediatric Patients

Rolsma S., Blackman M., Beck C., Dbouk A., Morovia F., Glover F., Ess G., Dohler K., Bridges B., Choi L., Creech C.B. Journal of the Pediatric Infectious Diseases Society. 2024 13 Supplement 4 (S9-S10)

评估高加索健康受试者中与体重相关的协变量对利福平PK的影响

Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers

Bilal M., Ullah S., Jaehde U., Trueck C., Zaremba D., Wachall B., Wargenau M., Scheidel B., Wiesen M.H.J., Gazzaz M., Chen C., Büsker S., Fuhr U., Taubert M., Dokos C. European Journal of Clinical Pharmacology. 2024 80:9 (1271-1283)

采用非线性混合效应模型对肥胖血液透析患者庆大霉素个体药代动力学参数进行估算

Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect model

Lee H., Yoon S., Chung J.Y. Translational and Clinical Pharmacology. 2024 32:3 (150-158)

利用定量药理学评估患者友好的伊维菌素 CHILD-IVITAB 在体重≥15 kg 和 <15 kg 儿童中的给药剂量

Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kg

Golhen K., Buettcher M., Huwyler J., van den Anker J., Gotta V., Dao K., Rothuizen L.E., Kobylinski K., Pfister M. Pharmaceutics. 2024 16:9 Article Number 1186

Elexacaftor/tezacaftor/ivacaftor 药代动力学与 2 至 5 岁儿童行为障碍的发生情况的研究

Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurance of behavioral disorders in children aged 2 to 5

Truong N., Benaboud S., Chouchana L., Bonnel A., Barboura M., Bouazza N., Gautier S., Rouillon S., Froelicher-Bournaud L., Bihouee T., Bui S., Treluyer J., Sermet-Gaudelus I., Foissac F. Journal of Cystic Fibrosis. 2024 23 Supplement 2 (S277-S278)

重症患者需增加头孢哌酮负荷剂量：一项采用PK建模评估推荐负荷剂量的回顾性研究

Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic Modelling

Launay M., Ollier E., Kably B., Le Louedec F., Thiery G., Lanoiselée J., Perinel-Ragey S. Antibiotics. 2024 13:8 Article Number 756

达沙替尼在健康受试者中的PopPK研究

Population Pharmacokinetics of Dasatinib in Healthy Subjects

Hassouneh W.B., Al-Ghazawi M.A., Saleh M.I., Najib N. Pharmaceuticals. 2024 17:6 Article Number 671

WS15.03 Elexacaftor/tezacaftor/ivacaftor 在囊性纤维化儿科患者中的PopPK研究

WS15.03 Elexacaftor/tezacaftor/ivacaftor population pharmacokinetics in paediatric patients with cystic fibrosis

Truong N.H., Benaboud S., Bardin E., et al. Journal of Cystic Fibrosis. 2024 23 Supplement 1 (S28-)

慢性髓性白血病患者体重指数与血浆中伊马替尼浓度的关系，并采用PK引导的给药策略减轻其临床影响

Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy

Maroselli P., Fanciullino R., Colle J., Farnault L., Rocher P., Venton G., Costello R., Ciccolini J. Journal of Clinical Oncology. 2024 42:16 Supplement

延长纳武利尤单抗给药间隔：在未筛选癌症患者中开展基于模型的模拟

Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients

Puszkiel A., Bianconi G., Pasquiers B., Balakirouchenane D., Arrondeau J., Boudou-Rouquette P., Bretagne M.-C., Salem J.-E., Declèves X., Vidal M., Kramkimel N., Guegan S., Aractingi S., Huillard O., Alexandre J., Wislez M., Goldwasser F., Blanchet B. British Journal of Cancer. 2024 130:11 (1866-1874)

RPEM：随机蒙特卡洛参数期望最大化算法

RPEM: Randomized Monte Carlo parametric expectation maximization algorithm

Chen R., Schumitzky A., Kryshchenko A., Nieforth K., Tomashevskiy M., Hu S., Garreau R., Otalvaro J., Yamada W., Neely M.N. CPT: Pharmacometrics and Systems Pharmacology. 2024 13:5 (759-780)

肺移植受者进行伊沙康唑治疗药物监测的理论依据

The Rationale for Therapeutic Drug Monitoring of Isavuconazole in a Lung Transplant Recipient

Zajacova A., Sima M., Havlin J., Klapkova E., Lischke R., Slanar O., Dvorackova E. Journal of Heart and Lung Transplantation. 2024 43:4 Supplement (S644-S645)

Lumacaftor/Ivacaftor 在囊性纤维化儿科患者中的PopPK：迈向个体化治疗的第一步

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy

Bouazza N., Urien S., Foissac F., Choupeaux L., et al. Clinical Pharmacokinetics. 2024 63:3 (333-342)

赖诺普利在高血压的儿童和正常至轻度肾功能受损的青少年的PopPK研究

Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney function

Sandra L., Degraeuwe E., De Bruyne P., De Baere S., Croubels S., Van Bocxlaer J.F.P., Raes A., Vande Walle J., Gasthuys E., Vermeulen A. British Journal of Clinical Pharmacology. 2024 90:2 (504-515)

基于模型的临床前试验心血管安全性评估与转化教程

A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials

Kulesh V., Vasyutin I., Volkova A., Peskov K., Kimko H., Sokolov V., Alluri R. CPT: Pharmacometrics and Systems Pharmacology 2024 13:1 (5-22)

提高奥拉帕利的药物暴露量以优化不良反应管理

Improving olaparib exposure to optimize adverse effects management

Sterlé M., Puszkiel A., Burlot C., Pereira E., Bellesoeur A., De Percin S., Beinse G., Fumet J.-D., Favier L., Niogret J., Blanchet B., Royer B., Bengrine-Lefevre L., Schmitt A. Therapeutic Advances in Medical Oncology. 2024 16

疑似急性肾移植排斥反应：甲基泼尼松龙治疗下他克莫司的药代动力学研究

Suspicious of Acute Kidney Graft Rejection: Tacrolimus Pharmacokinetics Under Methylprednisolone Therapy

Bidu N.S., Mattoso R.J.C., Santos O.A.C.O., Alves I.A., Fernandes B.J.D., Couto R.D. Current Drug Research Reviews. 2024 16:3 (403-411)